IDSA Top 3

Diabetic Foot Infection

IDSA GUIDELINES Apps brought to you free of charge courtesy of Guideline Central. All of these titles are available for purchase on our website, GuidelineCentral.com. Enjoy!

Issue link: https://eguideline.guidelinecentral.com/i/170607

Contents of this Issue

Navigation

Page 4 of 17

Treatment Selecting and Modifying an Antibiotic Regimen (See below for recommendations for antibiotic treatment of osteomyelitis) ÎClinically uninfected wounds should NOT be treated with antibiotics (SR-L). Î ÎÎPrescribe antibiotics for all infected wounds, but note that this is often insufficient unless combined with appropriate wound care (SR-L). ÎÎClinicians should select an empirical antibiotic regimen based on the severity of the infection and the likely etiologic agent(s) (SR-L). •  For mild to moderate infections in patients who have not recently received antibiotic treatment, target only aerobic Gram-positive cocci (GPC) (WR-L). ▶▶ Initial empiric therapy should be based on the severity of the infection and on any available microbiological data, such as recent culture results and the local prevalence of pathogens, especially antibiotic-resistant strains. •  For most severe infections, start broad-spectrum empiric antibiotics, pending culture results and antibiotic susceptibility data (SR-L). •  Empiric therapy directed at Pseudomonas aeruginosa is usually unnecessary except for patients with risk factors for true infection with this organism (SR-L). •  Consider providing empiric therapy directed against methicillin-resistant Staphylococcus aureus (MRSA) (WR-L): ▶▶ in a patient with a prior history of MRSA infection ▶▶ when the local prevalence of MRSA colonization or infection is high ▶▶ if the infection is clinically severe ÎÎBase definitive therapy on both the results of an appropriately obtained culture and sensitivity testing of a wound specimen and the patient's clinical response to the empiric regimen (SR-L). ÎÎBase the route of therapy largely on infection severity — parenteral therapy for all severe, and some moderate, DFIs, at least initially (WR-L), with a switch to oral agents when the patient is systemically well and culture results are available. •  Clinicians can probably use highly bioavailable oral antibiotics alone in most mild, and in many moderate, infections and topical therapy for selected mild superficial infections (SR-M). ÎÎContinue antibiotic therapy until, but not beyond, resolution of findings of infection, but not through complete healing of the wound (WR-L). •  An initial antibiotic course for a soft tissue infection is about 1-2 weeks for mild infections and 2-3 weeks for moderate to severe infections (WR-L). Osteomyelitis ÎÎConsider osteomyelitis as a potential complication of any infected, deep or large foot ulcer, especially one that is chronic or overlies a bony prominence (SR-M). ÎÎPerform a probe to bone (PTB) test for any DFI with an open wound. Note: When properly conducted and interpreted, it can help to diagnose (when the likelihood is high) or exclude (when the likelihood is low) diabetic foot osteomyelitis. (DFO) (SR-M). 3

Articles in this issue

Archives of this issue

view archives of IDSA Top 3 - Diabetic Foot Infection